secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kalaris Therapeutics, Inc. (KLRS)
CIK:        0001754068
Form:       8-K
Filed at:   2026-08-11T12:05:28+00:00
Accession:  0001193125-26-343477
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kalaris Q2 2026 net loss $11.5M; cash $93.5M funds operations into Q4 2027
--------------------------------------------------------------------------

- Net loss $11.5M for Q2 2026 vs $11.4M in Q2 2025; R&D expense $9.0M (up from $8.4M).
- Cash, equivalents and marketable securities $93.5M as of June 30, 2026, down from $118.0M at Dec 31, 2025.
- Phase 1b/2 TH103 study dosing ongoing; preliminary data expected 1H 2027; Phase 3 start on track for year-end 2027.
- Expanded Phase 1a data released, reinforcing BCVA, OCT, pharmacokinetic and time-to-retreatment findings.
- Leadership additions: Liisa Bayko as CFO (from Evercore ISI) and Laurie Keating to Board of Directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1754068/000119312526343477/0001193125-26-343477-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1754068/000119312526343477/d114296d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-343477

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer